Arcus Biosciences and Infinity Pharmaceuticals Partner to Evaluate Triple-Combination Therapy in Breast and Ovarian Cancer

Arcus Biosciences, Inc. (NYSE:RCUS) and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced on 6/26/2018 that they have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types which typically show minimal response to checkpoint inhibition monotherapy.